Title:
NOVEL USE OF ONCOLYTIC VIRUS
Document Type and Number:
WIPO Patent Application WO/2024/054040
Kind Code:
A1
Abstract:
The present invention relates to novel use of an oncolytic virus, and relates to an intravenously injectable composition for repeated administration, comprising, as an active ingredient, an oncolytic virus in which expression of a thymidine kinase (TK) gene is inhibited and genes encoding complement regulatory protein CD55 and granulocyte-macrophage colony-stimulating factor (GM-CSF) are inserted. In detail, the present invention relates to an intravenously injectable composition for repeated administration, comprising, as an active ingredient, an oncolytic virus in which: expression of a TK gene is inhibited; and a gene encoding CD55 fused with a transmembrane domain region of viral membrane protein to express the complement regulatory protein CD55 in an intracellular mature virion (IMV) membrane and a gene encoding the GM-CSF are inserted. Once administered into the human body, the composition of the present invention fuses with viral membrane protein H3, and due to CD55 expressed in the virus IMV membrane, avoids a neutralization reaction caused by antibodies, thereby enabling repeated intravenous administration of the oncolytic virus. In this regard, a reduction in anticancer efficacy by neutralizing antibodies can be prevented, and anticancer effects can be maximized.
More Like This:
Inventors:
OH KEUNHEE (KR)
LEE NAMHEE (KR)
PARK MI JU (KR)
HONG YUN KYOUNG (KR)
LEE NAMHEE (KR)
PARK MI JU (KR)
HONG YUN KYOUNG (KR)
Application Number:
PCT/KR2023/013363
Publication Date:
March 14, 2024
Filing Date:
September 06, 2023
Export Citation:
Assignee:
SILLAJEN INC (KR)
International Classes:
A61K35/76; A61K9/00; A61K38/17; A61K38/19; A61P35/00
Domestic Patent References:
| WO2018016917A1 | 2018-01-25 |
Foreign References:
| KR20220122551A | 2022-09-02 | |||
| KR20090122293A | 2009-11-26 | |||
| KR20200005721A | 2020-01-16 |
Other References:
DING YUEDI, FAN JUN, DENG LILI, PENG YING, ZHOU BIN, HUANG BIAO: "Evaluation of Tumor Specificity and Immunity of Thymidine Kinase-Deleted Vaccinia Virus Guang9 Strain", ONCOTARGETS AND THERAPY, vol. 13, 5 August 2020 (2020-08-05), pages 7683 - 7697, XP055961654, DOI: 10.2147/OTT.S260288
CHAURASIYA SHYAMBABU; CHEN NANHAI G.; LU JIANMING; MARTIN NIKOLAS; SHEN YINAN; KIM SANG-IN; WARNER SUSANNE G.; WOO YANGHEE; FONG Y: "A chimeric poxvirus with(thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models", CANCER GENE THERAPY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 3-4, 17 June 2019 (2019-06-17), New York, pages 125 - 135, XP037096068, ISSN: 0929-1903, DOI: 10.1038/s41417-019-0114-x
CHAURASIYA SHYAMBABU; CHEN NANHAI G.; LU JIANMING; MARTIN NIKOLAS; SHEN YINAN; KIM SANG-IN; WARNER SUSANNE G.; WOO YANGHEE; FONG Y: "A chimeric poxvirus with(thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models", CANCER GENE THERAPY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 27, no. 3-4, 17 June 2019 (2019-06-17), New York, pages 125 - 135, XP037096068, ISSN: 0929-1903, DOI: 10.1038/s41417-019-0114-x
Attorney, Agent or Firm:
YOON & YANG (IP) LLC (KR)
Download PDF: